suPAR: A New Biomarker for Cardiovascular Disease?

Gethin W Hodges; Casper N Bang; Kristian Wachtell; Jesper Eugen-Olsen; Jørgen L Jeppesen

doi:10.1016/j.cjca.2015.03.023

suPAR: A New Biomarker for Cardiovascular Disease?

Gethin W Hodges, Casper N Bang, Kristian Wachtell, Jesper Eugen-Olsen, Jørgen L Jeppesen

55 Citations (Scopus)

Abstract

The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

Original language	English
Journal	Canadian Journal of Cardiology
Volume	31
Issue number	10
Pages (from-to)	1293-302
Number of pages	10
ISSN	0828-282X
DOIs	https://doi.org/10.1016/j.cjca.2015.03.023
Publication status	Published - 1 Oct 2015

Keywords

Biomarkers
Cardiovascular Diseases
Humans
Inflammation
Predictive Value of Tests
Prognosis
Receptors, Urokinase Plasminogen Activator

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cjca.2015.03.023

Cite this

@article{e31b9dd32c6341bc9160bacb66b3b864,

title = "suPAR: A New Biomarker for Cardiovascular Disease?",

abstract = "The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.",

keywords = "Biomarkers, Cardiovascular Diseases, Humans, Inflammation, Predictive Value of Tests, Prognosis, Receptors, Urokinase Plasminogen Activator",

author = "Hodges, {Gethin W} and Bang, {Casper N} and Kristian Wachtell and Jesper Eugen-Olsen and Jeppesen, {J{\o}rgen L}",

year = "2015",

month = oct,

day = "1",

doi = "10.1016/j.cjca.2015.03.023",

language = "English",

volume = "31",

pages = "1293--302",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - suPAR

T2 - A New Biomarker for Cardiovascular Disease?

AU - Hodges, Gethin W

AU - Bang, Casper N

AU - Wachtell, Kristian

AU - Eugen-Olsen, Jesper

AU - Jeppesen, Jørgen L

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

AB - The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.

KW - Biomarkers

KW - Cardiovascular Diseases

KW - Humans

KW - Inflammation

KW - Predictive Value of Tests

KW - Prognosis

KW - Receptors, Urokinase Plasminogen Activator

U2 - 10.1016/j.cjca.2015.03.023

DO - 10.1016/j.cjca.2015.03.023

M3 - Review

C2 - 26118447

SN - 0828-282X

VL - 31

SP - 1293

EP - 1302

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 10

ER -

suPAR: A New Biomarker for Cardiovascular Disease?

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this